Victor M Lu1, Krishnan Ravindran2, Christopher S Graffeo2, Avital Perry2, Jamie J Van Gompel2, David J Daniels2, Michael J Link3. 1. Department of Neurosurgery, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. lu.victor@mayo.edu. 2. Department of Neurosurgery, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. 3. Department of Neurosurgery, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. link.michael@mayo.edu.
Abstract
BACKGROUND: Individual evidence suggests that the anti-angiogenic agent bevacizumab may control vestibular schwannoma (VS) growth and promote hearing preservation in patients with neurofibromatosis type 2 (NF2). However, such metadata has yet to be consolidated, as well as its side-effect profile yet to be fully understood. Our aim was to pool systematically-identified metadata in the literature and substantiate the clinical efficacy and safety of bevacizumab with respect to radiographic tumor response, hearing, and treatment outcomes. METHODS: Searches of seven electronic databases from inception to March 2019 were conducted following PRISMA guidelines. Articles were screened against pre-specified criteria. The incidence of outcomes was then extracted and pooled by random-effects meta-analysis of proportions. RESULTS: Eight articles reporting 161 NF2 patients with 196 assessable VS met satisfied all criteria. Radiographic response to bevacizumab was partial regression in 41% (95% CI 31-51%), no change in 47% (95% CI 39-55%), and tumor progression in 7% (95% CI 1-15%). In patients with assessable audiometric data, bevacizumab treatment resulted in hearing improvement in 20% (95% CI 9-33%), stability in 69% (95% CI 51-85%) and additional loss in 6% (95% CI 1-15%) Serious bevacizumab toxicity was observed in 17% (95% CI 10-26%). Subsequent surgical intervention was required in 11% (95% CI 2-20%). CONCLUSIONS: Bevacizumab may arrest both tumor progression and hearing loss in select NF2 patients presenting with VS lesions. However, a considerable proportion of patients are anticipated to experience serious adverse events; correspondingly, judicious use of bevacizumab for symptomatic management of VS in NF2 is recommended.
BACKGROUND: Individual evidence suggests that the anti-angiogenic agent bevacizumab may control vestibular schwannoma (VS) growth and promote hearing preservation in patients with neurofibromatosis type 2 (NF2). However, such metadata has yet to be consolidated, as well as its side-effect profile yet to be fully understood. Our aim was to pool systematically-identified metadata in the literature and substantiate the clinical efficacy and safety of bevacizumab with respect to radiographic tumor response, hearing, and treatment outcomes. METHODS: Searches of seven electronic databases from inception to March 2019 were conducted following PRISMA guidelines. Articles were screened against pre-specified criteria. The incidence of outcomes was then extracted and pooled by random-effects meta-analysis of proportions. RESULTS: Eight articles reporting 161 NF2patients with 196 assessable VS met satisfied all criteria. Radiographic response to bevacizumab was partial regression in 41% (95% CI 31-51%), no change in 47% (95% CI 39-55%), and tumor progression in 7% (95% CI 1-15%). In patients with assessable audiometric data, bevacizumab treatment resulted in hearing improvement in 20% (95% CI 9-33%), stability in 69% (95% CI 51-85%) and additional loss in 6% (95% CI 1-15%) Serious bevacizumabtoxicity was observed in 17% (95% CI 10-26%). Subsequent surgical intervention was required in 11% (95% CI 2-20%). CONCLUSIONS:Bevacizumab may arrest both tumor progression and hearing loss in select NF2patients presenting with VS lesions. However, a considerable proportion of patients are anticipated to experience serious adverse events; correspondingly, judicious use of bevacizumab for symptomatic management of VS in NF2 is recommended.
Entities:
Keywords:
Avastin; Bevacizumab; NF2; Neurofibromatosis type 2; Schwannoma
Authors: Sherif G Ahmed; Giulia Oliva; Manlin Shao; Xinhui Wang; John J Mekalanos; Gary J Brenner Journal: Proc Natl Acad Sci U S A Date: 2022-06-08 Impact factor: 12.779
Authors: Harish N Vasudevan; Calixto-Hope G Lucas; Javier E Villanueva-Meyer; Philip V Theodosopoulos; David R Raleigh Journal: Neurosurgery Date: 2021-01-13 Impact factor: 4.654
Authors: Muhammad Farooq; Nael Abutaha; Shahid Mahboob; Almohannad Baabbad; Nawaf D Almoutiri; Mohammad Ahmed A M Wadaan Journal: Saudi J Biol Sci Date: 2019-12-06 Impact factor: 4.219